Back to Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 5

Progress update: Pharmacological treatment of Alzheimer’s disease

Authors David B Hogan

Published 15 November 2007 Volume 2007:3(5) Pages 569—578

David B Hogan

Department of Medicine, University of Calgary, Alberta, Canada

Abstract: A number of drugs have been approved for the treatment of Alzheimer’s disease (AD) and a larger number are being studied as possible therapies. The current mainstays of the pharmacotherapy of AD are the cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. They collectively have acceptable tolerability and proven but modest efficacy. The agents being studied include dietary supplements (eg, vitamin E), herbal preparations (eg, Ginkgo biloba), medications approved for other indications (eg, HMG-CoA reductase enzyme inhibitors) and research drugs. In this review we discuss in detail the approved agents and review a number of the unapproved therapies that are currently available to the practitioner. While our era offers much more in the way of therapeutics for AD, it is clear that more work still needs to be done.

Keywords: Alzheimer’s disease, drug therapy, cholinesterase inhibitors

Download Article [PDF]